What is XELJANZ/XELJANZ XR?

XELJANZ/XELJANZ XR (tofacitinib) is a prescription medicine called a Janus kinase (JAK) inhibitor used to treat:

  • Adults with moderately to severely active rheumatoid arthritis in whom methotrexate did not work well

It is not known if XELJANZ/XELJANZ XR is safe and effective in children or in people with Hepatitis B or C.

XELJANZ/XELJANZ XR is not recommended for people with severe liver problems.

TRIAL Rx PROGRAM TERMS
AND CONDITIONS

  • This is not health insurance and is a one-time-only offer for eligible, commercially insured patients.
  • Offer is only available to patients who have been diagnosed with an FDA-approved indication for XELJANZ® XR (tofacitinib citrate) extended release.
  • Patients who have already begun therapy with XELJANZ XR at the time of the request and patients under the age of eighteen (18) years of age are ineligible for participation in the Program.
  • No claim for reimbursement for product dispensed pursuant to this offer may be submitted to any third-party private payer.
  • Not available to patients covered under government plans such as Medicaid, Medicare, or other federal or state healthcare programs, including any state prescription drug assistance programs and the Government Health Insurance Plan or for residents of Massachusetts.
  • Available in a 14-day supply.
  • This offer does not require, nor will be made contingent on, purchase requirements of any kind.
  • Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification.
  • Trial Rx can only be dispensed by the exclusive pharmacy and only after benefits investigation has been completed.
  • Additional eligibility criteria may apply. Contact XELSOURCE for details.

If you have questions or are in need of additional support, call 1-855-493-5526 or visit www.XELJANZ.com.

Pfizer Inc, 235 E. 42nd Street, New York, NY 10017

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

PATIENT ASSISTANCE PROGRAM/HARDSHIP
ASSISTANCE PROGRAM TERMS And CONDITIONS

  • The Patient Assistance Program/Hardship Assistance Program is not health insurance and is available for eligible patients with Medicaid insurance or eligible uninsured/underinsured patients only.
  • Offer is only available to patients who meet financial and other criteria.
  • This offer does not require, nor will it be made contingent on, purchase requirements of any kind.
  • No claim for reimbursement or credit for any costs associated with the medicine(s) may be submitted to any prescription insurance provider or payer, including Medicare Part D plans.
  • Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification.
  • Offer good only in the US and Puerto Rico.
  • Patient must be a resident of the United States or Puerto Rico.
  • Prescription must be provided by a healthcare provider licensed in the US or Puerto Rico.
  • Additional eligibility criteria may apply. Contact XELSOURCE for details.

If you have questions or are in need of additional support, call 1-855-493-5526 or visit www.XELJANZ.com.

Pfizer Inc, 235 E. 42nd Street, New York, NY 10017

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

Quick Facts

If moderate to severe rheumatoid arthritis (RA) joint pain is impacting your ability to do common daily activities—and methotrexate has not worked well—it may be time to ask if XELJANZ or the once-daily formulation, XELJANZ XR, could be right for you.
1A SMALL PILL

Not the only pill for adults with moderate to severe RA, XELJANZ (pronounced zel-janszel-janszel-jans) is an Unjection—one of a number
of oral prescription treatment options that is not an injection or infusion. XELJANZ is also available as a once-daily pill called XELJANZ XR. Learn more here.

2A JAK INHIBITOR

XELJANZ is the first FDA approved Janus kinase (JAK) inhibitor for adults with moderate to severe RA. If methotrexate hasn’t done enough to help relieve your moderate to severe RA symptoms, and before you and your rheumatologist decide on another treatment option, ask if XELJANZ could be an option for you.

3HELPS REDUCE FURTHER JOINT DAMAGE

X-rays have shown that XELJANZ helps reduce further joint damage.

4REDUCES RA JOINT PAIN AND SWELLING

In some patients, XELJANZ can begin to work in as early as 2 weeks to help relieve joint pain and swelling. For some it can take as long as 3 to 6 months.*

* Individual results
may vary

5CAN BE TAKEN ALONE

XELJANZ is a pill proven to reduce RA joint pain, swelling, and joint damage in adults with moderate to severe RA, even without methotrexate.

See Alison’s story.

6EASY-TO-OPEN BOTTLE

The easy-to-open XELJANZ bottle cap received the Arthritis Foundation’s Ease-of-Use Commendation.†

†The Arthritis Foundation’s Ease-of-Use Commendation recognizes products, such as the XELJANZ bottle cap, proven to make life easier for people who have arthritis and other physical limitations.

7COMMON SIDE EFFECTS

Common side effects of XELJANZ/XELJANZ XR in rheumatoid arthritis patients include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, and runny nose (nasopharyngitis), and high blood pressure (hypertension).

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit http://www.fda.gov/MedWatch or call 1-800-FDA-1088.

How XELJANZ Works

How Xeljanz Works
 
CLOSE X
 

XELJANZ is a Janus kinase (JAK) inhibitor that helps disrupt JAK pathways from inside the cells, which are believed to play a role in inflammation. Watch to learn more about the science of XELJANZ and how JAK inhibitors are thought to work.

By the Numbers

Since 2012, XELJANZ has been prescribed to more than 132,000 adult U.S. patients with moderate to severe rheumatoid arthritis.*

XELJANZ IS NOT AN INJECTION OR INFUSION.

 
adult patients in the U.S. have been prescribed XELJANZ for the treatment of their moderate to severe RA*. *Data Source: IQVIA Projected Retail & SPP claims (LRx); Office-Based Medical claims (Dx). Time Period: January 2013 through July 2018.

Individual results may vary.

In clinical studies, some XELJANZ
patients experienced a reduction in RA
joint pain and swelling in as early as 2
weeks. For some, it can take as long as
3 to 6 months.

Clinical Trial Results

The effectiveness of XELJANZ, taken with and without a disease-modifying antirheumatic drug (DMARD), such as methotrexate, was tested in six studies that involved more than 4,200 adult patients with moderate to severe RA.

   

In A Study More Than Half (59%) Of XELJANZ Patients Felt An Improvement In Their RA Symptoms Within 3 Months.†

In the ORAL Solo Study, at 2 weeks, 30% of XELJANZ patients (71 out of 240) and 12% of placebo patients (14 out of 119) experienced a 20% reduction in tender and swollen joint counts and 3 of these 5 indicators: blood test that measures inflammation, patient assessment, physician assessment, pain scale, and disability/functional questionnaire. These measures are in accordance with the ACR20, a measuring standard that shows 20% or greater improvement of symptoms.

At 3 months, 59% of XELJANZ patients (143 out of 243) and 25% of placebo patients (31 out of 122) experienced an improvement in ACR20 scores. During this study, patients did not take methotrexate.

†Individual results may vary.

At 3 Months, More Than Half Of XELJANZ Patients Could More Easily Complete Common Daily Activities, Such As Getting Dressed, Walking Down Stairs, And Gripping Household Items.

In the ORAL Solo Study, a scale was used that defines RA disability as: 0-1 = mild; 1-2 = moderate to severe; 2+ = greater disability. At the study start, XELJANZ patients had a mean baseline score of 1.53.

At 3 months, XELJANZ patients saw an improved score of 1.05 (a statistically important difference) and, overall, 60% (143 out of 240) of XELJANZ patients experienced an improvement of ≥0.22 on the Health Assessment Questionnaire Disability Index (HAQ-DI) that assesses the following categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. During this study, patients did not take methotrexate.

XELJANZ Reduced Further Joint Pain And Swelling Caused By RA, Even Without The Use Of Methotrexate.

In the ORAL Solo Study, at 2 weeks, 30% of XELJANZ patients (71 out of 240) and 12% of placebo patients (14 out of 119) experienced a 20% reduction in tender and swollen joint counts and 3 of these 5 indicators: blood test that measures inflammation, patient assessment, physician assessment, pain scale, and disability/functional questionnaire.

At 3 months, 59% of XELJANZ patients (143 out of 243) and 25% of placebo patients (31 out of 122) experienced the same results. During this study, patients did not take methotrexate.

At 6 Months, XELJANZ Patients Experienced Less RA Joint Damage Progression Than Methotrexate Patients.

Based on two studies, XELJANZ was shown on X-rays to help reduce further structural joint damage.

In the ORAL Start Study, patients hadn't taken methotrexate prior to the study. However, XELJANZ is only approved for use in patients for whom methotrexate did not work well. At 6 months, XELJANZ patients got worse by 0.2 units of change on the modified Total Sharp Score (mTSS) scale, while patients taking methotrexate worsened by 0.8. mTSS measures joint damage progression in selected joints of the hands and feet. The higher the amount of change in the mTSS, the more joint damage has progressed.

In the ORAL Scan Study, patients who took XELJANZ and methotrexate had less progression of RA joint damage after 6 months (0.1) than those who took a placebo and methotrexate (0.5). However, the possibility was high enough that the difference between treatments may have been due to chance alone and not due to XELJANZ, so the results were not considered significant.
       

    Safety & Side Effects

    Close X

    SERIOUS INFECTIONS

    Serious infections.

    XELJANZ/XELJANZ XR can lower the ability of your immune system to fight infections. Some people can have serious infections while taking XELJANZ/XELJANZ XR, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.

    • Your healthcare provider should test you for TB before starting and during XELJANZ/XELJANZ XR treatment, and monitor you closely for signs and symptoms of TB infection during treatment.

    You should not start taking XELJANZ/XELJANZ XR if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster). People taking the higher dose (10 mg twice daily) of XELJANZ have a higher risk of serious infections and shingles.

    Before starting XELJANZ/XELJANZ XR, tell your healthcare provider if you:

    • think you have an infection or have symptoms of an infection, such as fever, sweating, or chills; cough; blood in phlegm; warm, red, or painful skin or sores on your body; burning when you urinate or urinating more often than normal; muscle aches; shortness of breath; weight loss; diarrhea or stomach pain; or feeling very tired
    • are being treated for an infection
    • get a lot of infections or have infections that keep coming back
    • have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections
    • have TB, or have been in close contact with someone with TB
    • live or have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, or blastomycosis). These infections may happen or become more severe if you use XELJANZ/XELJANZ XR. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common
    • have or have had Hepatitis B or C

    After starting XELJANZ/XELJANZ XR, call your healthcare provider right away if you have any symptoms of an infection. XELJANZ/XELJANZ XR can make you more likely to get infections or make worse any infection that you have.

    Close X

    CANCER AND IMMUNE SYSTEM PROBLEMS

    Cancer and immune system problems.

    XELJANZ/XELJANZ XR may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen in patients taking XELJANZ/XELJANZ XR. People taking the higher dose (10 mg twice daily) of XELJANZ have a higher risk of skin cancers. Tell your healthcare provider if you have ever had any type of cancer.

    Some people who have taken XELJANZ with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).

    Close X

    TEARS (PERFORATION) IN THE STOMACH OR INTESTINES

    Tears (perforation) in the stomach or intestines.

    Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ/XELJANZ XR can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever and stomach-area pain that does not go away and a change in your bowel habits.

    Close X

    SERIOUS ALLERGIC REACTIONS

    Serious allergic reactions.

    Serious allergic reactions have happened in patients taking XELJANZ/XELJANZ XR. If you have swelling of your lips, tongue, throat, or get hives, stop XELJANZ/XELJANZ XR and call your healthcare provider right away.

    Close X

    CHANGES IN CERTAIN LAB TEST RESULTS

    Changes in certain lab test results.

    Your healthcare provider should do blood tests before you start receiving XELJANZ/XELJANZ XR, and while you take XELJANZ/XELJANZ XR, to check for the following side effects:

    • Changes in lymphocyte counts. Lymphocytes are white blood cells that help the body fight off infections.
    • Low neutrophil counts. Neutrophils are white blood cells that help the body fight off infections.
    • Low red blood cell count. This may mean that you have anemia, which may make you feel weak and tired.

    Your healthcare provider should routinely check certain liver tests.

    You should not receive XELJANZ/XELJANZ XR if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver tests are too high. Your healthcare provider may stop your XELJANZ/XELJANZ XR treatment for a period of time if needed because of changes in these blood test results.

    You may also have changes in other laboratory tests, such as your blood cholesterol levels. Your healthcare provider should do blood tests to check your cholesterol levels 4 to 8 weeks after you start XELJANZ/XELJANZ XR, and as needed after that.

    Close X

    WHAT SHOULD I TELL MY HEALTHCARE PROVIDER BEFORE TAKING XELJANZ/XELJANZ XR?

    What should I tell my healthcare provider before taking XELJANZ/XELJANZ XR?

    Before taking XELJANZ/XELJANZ XR, tell your healthcare provider about all of your medical conditions, including if you:

    • have an infection
    • have liver problems
    • have kidney problems
    • have any stomach area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
    • have had a reaction to tofacitinib or any of the ingredients in XELJANZ/XELJANZ XR
    • have recently received or are scheduled to receive a vaccine. People taking XELJANZ/XELJANZ XR should not receive live vaccines but can receive non-live vaccines
    • plan to become pregnant or are pregnant. XELJANZ/XELJANZ XR may affect the ability of females to get pregnant. It is not known if this will change after stopping XELJANZ/XELJANZ XR. It is not known if XELJANZ/XELJANZ XR will harm an unborn baby.
      • Pregnancy Registry: Pfizer has a registry for pregnant women who take XELJANZ/XELJANZ XR. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking XELJANZ/XELJANZ XR, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1‐877‐311‐8972 to enroll
    • plan to breastfeed or are breastfeeding. You and your healthcare provider should decide if you will take XELJANZ/XELJANZ XR or breastfeed. You should not do both. After you stop your treatment with XELJANZ/XELJANZ XR do not start breastfeeding again until 18 hours after your last dose of XELJANZ or 36 hours after your last dose of XELJANZ XR.
    • Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take any other medicines to treat your rheumatoid arthritis or psoriatic arthritis. You should not take tocilizumab (Actemra®), etanercept (Enbrel®), adalimumab (Humira®), infliximab (Remicade®), rituximab (Rituxan®), abatacept (Orencia®), anakinra (Kineret®), certolizumab (Cimzia®), golimumab (Simponi®), ustekinumab (Stelara®), secukinumab (Cosentyx®), vedolizumab (Entyvio®), azathioprine, cyclosporine, or other immunosuppressive drugs while you are taking XELJANZ or XELJANZ XR. Taking XELJANZ or XELJANZ XR with these medicines may increase your risk of infection.
    • Tell your healthcare provider if you are taking medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.

    Close X

    WHAT ARE OTHER POSSIBLE SIDE EFFECTS OF XELJANZ/XELJANZ XR?

    What are other possible side effects of XELJANZ/XELJANZ XR?

    XELJANZ/XELJANZ XR may cause serious side effects, including Hepatitis B or C activation infection in people who carry the virus in their blood. If you are a carrier of the Hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ/XELJANZ XR. Your healthcare provider may do blood tests before you start treatment with XELJANZ/XELJANZ XR and while you are using XELJANZ/XELJANZ XR. Tell your healthcare provider if you have any of the following symptoms of a possible Hepatitis B or C infection: feel very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach discomfort, or dark urine.

    Common side effects of XELJANZ/XELJANZ XR in rheumatoid arthritis and psoriatic arthritis patients include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, and runny nose (nasopharyngitis), and high blood pressure (hypertension).

    These are not all of the possible side effects of XELJANZ/XELJANZ XR. Please see the Prescribing Information, including BOXED WARNING and Medication Guide, for additional information and complete details about XELJANZ.

    REQUEST MORE INFO ABOUT XELJANZ.